First Trust Advisors
TSHA icon

First Trust Advisors’s Taysha Gene Therapies TSHA Stock Holding History

First Trust Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.39M Buy
+791,169
New +$4.68M ﹤0.01% 1537

Other funds holding TSHA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
AWM
Affinity Wealth Management Wilmington, Delaware $776M AUM 43.59% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

First Trust Advisors's TSHA Position: Q2 2026 in Review

First Trust Advisors opened a new position in Taysha Gene Therapies (TSHA) in Q2 2026: 791,169 shares worth $5.39M. The stake represents ﹤0.01% of the portfolio and ranks #1537 among its holdings.

80 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • First Trust Advisors held 791,169 shares of Taysha Gene Therapies worth $5.39M as of Q2 2026.
  • Taysha Gene Therapies was a new First Trust Advisors position in Q2 2026.
  • Taysha Gene Therapies made up ﹤0.01% of First Trust Advisors's portfolio in Q2 2026, its #1537 holding.
  • 80 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.